Immunic, Inc.: Participation in Upcoming Scientific and Investor Conferences
Immunic, Inc., a pioneering biotechnology company, is set to showcase its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases at several upcoming scientific and investor conferences in March 2025.
34th Annual Meeting of the Society for Virology
First, Immunic will attend the 34th Annual Meeting of the Society for Virology, taking place in Hamburg, Germany from March 4-7, 2025. This esteemed scientific conference brings together leading researchers and experts from around the world to discuss the latest developments in virology. Immunic has been granted the opportunity to present two abstracts as part of the conference:
- Abstract 1: This presentation will focus on the company’s lead candidate, IMU-838, a selective immune modulator that targets the NLRP3 inflammasome, which plays a significant role in various inflammatory and autoimmune diseases. The abstract will detail the results of preclinical studies demonstrating IMU-838’s efficacy in treating viral hepatitis.
- Abstract 2: The second abstract will discuss the potential of IMU-838 in the treatment of COVID-19, presenting data from preclinical studies that suggest the drug could help reduce the severity of the disease and prevent complications.
Impact on Individuals
For individuals living with chronic inflammatory and autoimmune diseases, the potential advancements in the treatment of viral hepatitis and COVID-19 through Immunic’s IMU-838 could bring significant relief. Chronic hepatitis B and C affect millions of people worldwide, leading to liver damage, cirrhosis, and even liver cancer if left untreated. IMU-838’s ability to target the NLRP3 inflammasome could lead to more effective and tolerable treatments for these debilitating diseases. Additionally, the potential application of IMU-838 in the treatment of COVID-19 could help reduce the severity of symptoms and prevent complications for those infected.
Impact on the World
The global impact of the research presented by Immunic at the 34th Annual Meeting of the Society for Virology could be profound. Chronic viral hepatitis affects an estimated 325 million people worldwide, resulting in approximately 1.4 million deaths each year. Effective and tolerable treatments for these diseases could save countless lives and significantly improve the quality of life for millions of people. Furthermore, the potential application of IMU-838 in the treatment of COVID-19 could help reduce the global burden of the ongoing pandemic. With over 400 million confirmed cases and 5 million deaths to date, the development of safe and effective treatments for COVID-19 remains a top priority.
Conclusion
Immunic, Inc.’s participation in the 34th Annual Meeting of the Society for Virology marks an exciting step forward in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, including viral hepatitis and COVID-19. The potential impact on individuals living with these conditions and the global community as a whole could be substantial, offering hope for improved treatments and ultimately, better health outcomes.
As the scientific community continues to explore the potential of IMU-838, it is essential to stay informed about the latest developments in this field. By attending these conferences and engaging in ongoing research, Immunic is paving the way for a brighter future in the treatment of chronic inflammatory and autoimmune diseases. Stay tuned for further updates on this promising biotechnology company and the groundbreaking research it is conducting.
